BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.28x

BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow Reinvestment Rate of 0.28x as of December 2025, reinvesting $77.31 Million (capex $802.00K plus investments $-76.50 Million) from operating cash flow of $276.04 Million. Explore BioCryst Pharmaceuticals Inc (BCRX) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.28x

(Capex + Investments) / Operating CF

Total Reinvested

$77.31 Million

Capex + Investments

Operating Cash Flow

$276.04 Million

USD

Capital Expenditures

$802.00K

USD

BioCryst Pharmaceuticals Inc Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for BioCryst Pharmaceuticals Inc across 1 annual periods. Also explore BCRX asset base for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for BioCryst Pharmaceuticals Inc (2025–2025)

Year-by-year capital reinvestment analysis for BioCryst Pharmaceuticals Inc. For live market cap and broader valuation context, see how much is BioCryst Pharmaceuticals Inc worth.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2025	0.02x	$8.06 Million	$329.88 Million	$2.47 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow